Dr Martens, a renowned boot manufacturer, is anticipating a significant financial impact from US tariffs this year. The company, famous for its iconic footwear, now primarily produces its products in Vietnam, a move triggered by the escalated import duties resulting from the trade tensions fueled by US President Donald Trump’s policies. Dr Martens expects a multimillion-pound dent in its profits due to the tariffs, projecting a “high single digit” million-pound hit for the full year.
Having already transitioned its production away from China, which previously contributed 50% of its manufacturing, Dr Martens has taken measures to mitigate the impact of higher US import tariffs. Despite the tariff challenges, the company remains confident in achieving its full-year profit forecast range of £53 million to £60 million before tax, excluding the tariff impact.
Following this announcement, Dr Martens’ stock prices experienced a notable decline, dropping over 10% during early trading hours on Thursday. The company, synonymous with its yellow-stitched boots that have enjoyed enduring popularity over the years, plans to completely offset the additional tariff costs starting from the upcoming year. It aims to achieve this through stringent cost management, strategic product sourcing, and targeted adjustments to its pricing strategy in the USA.
The update on tariffs coincided with the release of half-year financial results, revealing that Dr Martens had reduced its losses to £11 million for the six months ending September 28, down from £12.3 million in the previous year. Additionally, the company reported a 0.8% increase in sales to £327.3 million in the first half of the year.
Dr. Ije Nwokorie, the CEO of Dr Martens, expressed satisfaction with the brand’s performance, citing a 33% rise in shoe volumes and successful launches of new products like the Zebzag Laceless boot and the 1460 Rain boot. Despite acknowledging market uncertainties and consumer caution, Nwokorie remains optimistic about the company’s prospects for the year ahead.
Russ Mould, the investment director at broker AJ Bell, acknowledged the progress made by Dr Martens in its turnaround efforts. While praising the improvements in product pricing, narrowed losses, and stronger performance in the Americas region, Mould cautioned that the recovery process might be gradual rather than swift. The market response to the half-year results was mixed, with a drop in share prices during early trading reflecting some investor disappointment.